Effects of Hazelnuts and Cocoa on Metabolic Parameters and Vascular Reactivity
NCT ID: NCT02845622
Last Updated: 2016-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
61 participants
INTERVENTIONAL
2014-06-30
2015-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
group 1) 30 g peeled hazelnuts;
group 2) 30 g unpeeled hazelnuts;
group 3) snack with 30 g peeled hazelnuts;
group 4) snack with 2.5 g cocoa powder;
group 5) snack with 30 g peeled hazelnuts and 2.5 g cocoa;
group 6) empty snack, control group.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects
NCT02149238
Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension
NCT01672840
High Flavonols Cocoa Intake for the Improvement of Body Fat Composition in Athletes
NCT04028128
Cocoa Flavanol and Coronary Vasomotion Vascular Function in Patients With Coronary Artery Disease
NCT02520466
Effects of Cocoa Products on Cardiovascular Disease Risk Factors
NCT00511420
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
30g peeled hazelnuts cream
Every person in this group will receive a 30 g peeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
Hazelnut
This dietary supplement contains 30 g of hazelnut.
Cream
This dietary supplement is just a cream obtained by grinding hazelnuts.
30g unpeeled hazelnuts cream
Every person in this group will receive a 30 g unpeeled hazelnuts cream as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
Hazelnut
This dietary supplement contains 30 g of hazelnut.
Cream
This dietary supplement is just a cream obtained by grinding hazelnuts.
snack w/ 30g peeled hazelnuts
Every person in this group will receive a snack with 30 g peeled hazelnuts as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
Hazelnut
This dietary supplement contains 30 g of hazelnut.
Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
snack w/ 2.5g cocoa powder
Every person in this group will receive a snack with 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
Cocoa
This dietary supplement contains 2.5 g of cocoa powder.
Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
snack w/ 30g peeled hazelnuts+2.5g cocoa
Every person in this group will receive a snack with 30 g peeled hazelnuts and 2.5 g cocoa powder as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
Hazelnut
This dietary supplement contains 30 g of hazelnut.
Cocoa
This dietary supplement contains 2.5 g of cocoa powder.
Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
empty snack
Every person in this group will receive an empty snack as an integration to his usual breakfast, and will be asked not to change his diet and physical activity during the 2-week trial.
No hazelnuts / No cocoa
This dietary supplement does not contain hazelnut nor cocoa powder.
Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hazelnut
This dietary supplement contains 30 g of hazelnut.
Cocoa
This dietary supplement contains 2.5 g of cocoa powder.
No hazelnuts / No cocoa
This dietary supplement does not contain hazelnut nor cocoa powder.
Cream
This dietary supplement is just a cream obtained by grinding hazelnuts.
Snack
This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* glucose intolerance
* dyslipidemia
* metabolic syndrome
* allergies
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Soremartec Italia S.r.l.
UNKNOWN
Ospedale San Donato
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Anna Ferrulli
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
San Donato Hospital
San Donato Milanese, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sartori TE, Nunes RA, da Silva GT, da Silva SC, Rondon MU, Negrao CE, Mansur AJ. Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease. Vasc Health Risk Manag. 2010 Jun 1;6:431-7. doi: 10.2147/vhrm.s10683.
Acree LS, Comp PC, Whitsett TL, Montgomery PS, Nickel KJ, Fjeldstad AS, Fjeldstad C, Gardner AW. The influence of obesity on calf blood flow and vascular reactivity in older adults. Dyn Med. 2007 Mar 26;6:4. doi: 10.1186/1476-5918-6-4.
Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics-brachial artery reactivity study). Am J Cardiol. 2004 Aug 1;94(3):294-9. doi: 10.1016/j.amjcard.2004.04.022.
Chandran DS, Jaryal AK, Jyotsna VP, Deepak KK. Impaired endothelium mediated vascular reactivity in endogenous Cushing's syndrome. Endocr J. 2011;58(9):789-99. doi: 10.1507/endocrj.ej11-0030. Epub 2011 Jul 21.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Nocciola/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.